Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 7 open-market purchases and 8 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:24 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 11, 2025 |
| Operating expenses | $125.1M | $83.1M |
| Research and development | $94.8M | $60.9M |
| Selling, general and administrative | $30.3M | $22.1M |
| Operating income | -$125.1M | -$83.1M |
| Income tax | $0 | $0 |
| Net income | -$111.5M | -$78.3M |
| EPS, basic | $-2.86 | $-3.78 |
| EPS, diluted | $-2.86 | $-3.78 |
| Weighted shares, basic | 38.9M | 20.7M |
| Weighted shares, diluted | 38.9M | 20.7M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 11, 2025 |
| Cash and equivalents | $52.6M | $56.8M |
| Short-term investments | $437.9M | $248.5M |
| Total current assets | $498.6M | $309.8M |
| Property, plant and equipment | $2.98M | $3.53M |
| Total assets | $512.4M | $314.9M |
| Accounts payable | $4.19M | $1.95M |
| Total current liabilities | $19.0M | $8.77M |
| Total liabilities | $27.8M | $9.51M |
| Shareholders' equity | $484.7M | $305.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2026 | Mar 11, 2025 |
| Operating cash flow | -$87.5M | -$64.8M |
| Capital expenditures | $616.0K | $2.40M |
| Free cash flow | -$88.1M | -$67.2M |
| Depreciation and amortization | $1.02M | $839.0K |
| Stock-based compensation | $18.9M | $10.2M |
| Investing cash flow | -$187.5M | -$170.1M |
| Financing cash flow | $270.8M | $221.6M |
| Net change in cash | -$4.16M | -$13.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 59.3M | +24.4% | SEC |
| Aug 3, 2026 | 48.0M | +31.5% | SEC |
| May 4, 2026 | 47.8M | +31.0% | SEC |
| Mar 2, 2026 | 47.8M | +31.0% | SEC |
| Nov 4, 2025 | 47.7M | +30.3% | SEC |
| Aug 4, 2025 | 36.5M | −0.2% | SEC |
| May 6, 2025 | 36.5M | – | SEC |
| Mar 1, 2025 | 36.5M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.